Measures for the reimbursement of advanced therapies
By | translator Alice Kang
21.04.14 06:00:45
°¡³ª´Ù¶ó
0
Advanced therapies have the potential to cure severe diseases¡¦perception of' high price' needs to be reconsidered
The existing ICER threshold cannot adequately assess the value of new drugs ¡¦ flexible application is necessary
The release of the CAR-T treatment ¡®Kymriah (tisagenlecleucel)¡¯ in Korea was met with both anticipation and concerns. The drug itself is undeniably an innovative drug that can offer new opportunities to blood cancer patients with short life expectancy. However, the challenge lies in how this innovative new drug that costs 500 million won per dose should be listed for reimbursement in Korea¡¯s healthcare system.
Clearly, these advanced drugs cannot be evaluated under the same standards as existing drugs. The development trend of new drugs has already shifted towards the treatment of severe or rare diseases, and gene and cell therapies that combine new science and technology occupy a large proportion of de
(same@dailypharm.com)
If you want to see the full article, please JOIN US (click)